BiotechTube

CTX-009 (ABL001) + Paclitaxel + Irinotecan

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

P1b: Advanced Solid Tumors

Conditions

P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer

Trial Timeline

Jun 22, 2020 → Jan 9, 2025

NCT ID
NCT04492033

About CTX-009 (ABL001) + Paclitaxel + Irinotecan

CTX-009 (ABL001) + Paclitaxel + Irinotecan is a phase 1/2 stage product being developed by Compass Therapeutics for P1b: Advanced Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT04492033. Target conditions include P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04492033Phase 1/2Terminated

Other Products from Compass Therapeutics

CTX-009 + PaclitaxelPhase 2/3
60
CTX-009Phase 2
47
CTX-009 + CTX-471Phase 1/2
36
Gemcitabine + Cisplatin + Durvalumab + CTX-009Phase 1/2
36
CTX-10726Phase 1
28